Pfizer is one of the world's largest pharmaceutical firms, with annual sales over $50 billion. Pfizer also spends a leading amount on research and development, close to $8 billion annually. While Pfizer historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, neuroscience drug Lyrica, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor, representing over a fifth of total firm sales.

PILGRIM'S PRIDE CORP has an Investment Rating of HOLD; a target price of $17.000000; an Industry Subrating of Low; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of High.

STERIS PLC has an Investment Rating of HOLD; a target price of $197.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.

Pilgrim’s Pride is the second-largest poultry producer in the U.S. (67% of 2019 sales), the U.K. (21%), and Mexico (12%). The 2019 purchase of Tulip Limited, the U.K.'s largest hog producer, marks the firm's entrance into the pork market, which we expect to represent about 10% of sales. Pilgrim sells its protein to chain restaurants, food processors, and retail chains, under brand names Pilgrim’s, Country Pride, Gold’n Plump, and Just Bare. Channel exposure is split evenly between retail and food service, with the majority of food-service revenue coming from quick-service restaurants. JBS owns 79% of Pilgrim’s outstanding shares.